CONCORD, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) and Grifols S.A. (MCE:GRF) today announced that the two companies have entered into an agreement extending Grifols’ INTERCEPT platelet and plasma distribution territory to include Italy. The INTERCEPT Blood System inactivates a broad range of viruses, bacteria and parasites that may contaminate donated blood components, including emerging pathogens such as West Nile virus, Chikungunya and influenza virus.
